2Han KH,Park JY.Chemotherapy for advanced hepatocellular carcinoma[J].J Gastroenterol Hepatol,2008,23:811-816.
3Okada S,Okazaki N,Nose H,et al.A phase 2 study of cisplatin in patients with hepatocellular carcinoma[J].Oncology,1993,50(1):22-26.
4Yen Y,Doroshow J,Leong L,et al.Phase Ⅱ study of oxaliplatin in patients with unresectable,metastatic or recurrent hepatocellular cancer[J].Proc Am Soc Clin Oncol,2004,Abstract 4169.
5Qin Sk,Wang YJ,Wu Q,et al.Clinical study of systemic using FOLFOX4 regimen in chinese patients with inoperable primary liver cancer[C].Gastrointestinal Cancers Symposium,2007:a151.
6Adjei AA.Clinical studies of pemetrexed and gemcitabine combinations[J].Ann Oncol 2006,(suppl 5):v29-v32.
7Bjm H,Gmbrg RM,Bremnes YF,et al.Phase Ⅲ study y the Norwegian lung cancer group pemetrexed plus carboplatin compared with gem citabine plus carbolatin as first-line chemotherapy in advanced non-small-cell lung cancer[J].J Clin Oncol,2009,27 (19):3217-3224.
8Kaneko S, Urahe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis [ J ]. Oneology, 2002,62 ( Suppl 1 ) :69 -73.
9Chou T C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs on enzyme inhibitors [ J ]. Adv Enzyme Regul, 1984, 22(1): 27-30.
10Harrington D J, Iessey B A, Rai V. et al. Tenascin is differentially expressed in endometrium and endometriosis[J]. J Pathol, 1999, 187(2):242 - 248.
1Peck-Radosavljevic M, Sieghart W, Kolblinger C, et al. Austrian Joint OGGH-OGIR OGHO-ASS0 position statement on the use of transarterial chemoembolization ( TACE ) in hepatocellular carcinoma [J]. Wien Klin Wochenschr, 2012,124 (3/4) : 104-110.
2Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin in patients with advanced hepatocellular carcinoma: results of a phase II study [J]. Cancer, 2007, 109(7):1384- 1390.
4Forner A, Gilabert M, Bruix J, et al. Treatment of intermediate-stage hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2014, 11(9): 525-535.
5Sieghart W, Hueke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatoeellular carcinoma[J]. Hepatology, 2013, 57(6): 2261-2273.
6Arjaans M, Oude Munnink TH, Oosting SF, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake [J]. Cancer Res, 2013, 73 (11): 3347-3355.
